Pfizer has regrouped in the GLP-1 space and is now working on a long-acting drug option. The company's update on the drug's development progress suggests it can compete with GLP-1 drugs from Eli Lilly ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. The company purchased Metsera in November for up to $10 billion to reignite its ...

Pfizer is rated a buy due to its robust drug pipeline, focus on improving financials, and significant long-term growth potential despite near-term headwinds. PFE delivered strong results in H1, with ...

SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic ...

Connecticut-based Pfizer Inc. said Thursday that it has completed the successful acquisition of Metsera, Inc., which is “a clinical-stage biopharmaceutical company accelerating the next generation of ...

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk.

BRUSSELS, June 23 (Reuters) - China has pulled ahead of Europe in pharmaceutical innovation and drug development, a senior Pfizer (PFE.N), opens new tab executive said on Tuesday. China has become a ...

Pfizer has won a $10 billion deal to acquire the fast-rising obesity drug developer Metsera, ending a fierce bidding war with Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer ...

Novo's $10 billion offer deemed superior by Metsera Pfizer files lawsuits against Metsera and Novo Nordisk Pfizer raises 2025 profit forecast amid declining COVID-19 sales Delaware Judge suggests ...

Pfizer (NYSE:PFE) moves into focus as healthcare earnings and merger activity reshape conditions across the pharmaceutical ...

As noted, Merck and Pfizer are both large pharmaceutical companies. Making and selling drugs is complex, expensive, and competitive. There are massive research and development costs involved in ...